{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:36Z","timestamp":1786982676197,"version":"build-2736575974"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s13555-021-00612-x","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T12:45:06Z","timestamp":1633869906000},"page":"1917-1929","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options"],"prefix":"10.1007","volume":"11","author":[{"given":"Alan","family":"Menter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby S.","family":"Van Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,9]]},"reference":[{"key":"612_CR1","first-page":"131","volume":"6","author":"KE Benjegerdes","year":"2016","unstructured":"Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131\u201344.","journal-title":"Psoriasis (Auckl)"},{"key":"612_CR2","doi-asserted-by":"publisher","first-page":"adv00034","DOI":"10.2340\/00015555-3388","volume":"100","author":"H Bachelez","year":"2020","unstructured":"Bachelez H. Pustular psoriasis: the dawn of a new era. Acta Derm Venereol. 2020;100:adv00034.","journal-title":"Acta Derm Venereol"},{"key":"612_CR3","first-page":"169","volume":"24","author":"F Ciccarelli","year":"2016","unstructured":"Ciccarelli F, De Martinis M, Sirufo MM, Ginaldi L. Psoriasis induced by anti-tumor necrosis factor alpha agents: a comprehensive review of the literature. Acta Dermatovenerol Croat. 2016;24:169\u201374.","journal-title":"Acta Dermatovenerol Croat"},{"key":"612_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1684\/ejd.2020.3702","volume":"30","author":"R Mossner","year":"2020","unstructured":"Mossner R, Pinter A. Paradoxical palmoplantar pustulosis induced by secukinumab and brodalumab: a report of three cases. Eur J Dermatol. 2020;30:177\u20138.","journal-title":"Eur J Dermatol"},{"key":"612_CR5","doi-asserted-by":"publisher","first-page":"e13332","DOI":"10.1111\/dth.13332","volume":"33","author":"M Satoh","year":"2020","unstructured":"Satoh M, Yamamoto T. Secukinumab-induced palmar vesiculopustular eruption in a patient with psoriasis. Dermatol Ther. 2020;33:e13332.","journal-title":"Dermatol Ther"},{"key":"612_CR6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029\u201372.","journal-title":"J Am Acad Dermatol"},{"key":"612_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.19039","volume":"183","author":"CH Smith","year":"2020","unstructured":"Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183:628\u201337.","journal-title":"Br J Dermatol"},{"key":"612_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/1744666X.2019.1708194","volume":"16","author":"S Kharawala","year":"2020","unstructured":"Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of palmoplantar pustulosis: a structured review. Expert Rev Clin Immunol. 2020;16:253\u201366.","journal-title":"Expert Rev Clin Immunol"},{"key":"612_CR9","doi-asserted-by":"publisher","first-page":"e006450","DOI":"10.1136\/bmjopen-2014-006450","volume":"5","author":"K Kubota","year":"2015","unstructured":"Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5:e006450.","journal-title":"BMJ Open"},{"key":"612_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40257-020-00503-5","volume":"21","author":"M Misiak-Galazka","year":"2020","unstructured":"Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020;21:355\u201370.","journal-title":"Am J Clin Dermatol"},{"key":"612_CR11","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/jdv.14386","volume":"31","author":"AA Navarini","year":"2017","unstructured":"Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1792\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"612_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","volume":"143","author":"S Twelves","year":"2019","unstructured":"Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143:1021\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"612_CR13","first-page":"109","volume":"26","author":"M Misiak-Galazka","year":"2018","unstructured":"Misiak-Galazka M, Wolska H, Galazka A, Kwiek B, Rudnicka L. General characteristics and comorbidities in patients with palmoplantar pustulosis. Acta Dermatovenerol Croat. 2018;26:109\u201318.","journal-title":"Acta Dermatovenerol Croat"},{"key":"612_CR14","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/1346-8138.13751","volume":"44","author":"M Kouno","year":"2017","unstructured":"Kouno M, Nishiyama A, Minabe M, et al. Retrospective analysis of the clinical response of palmoplantar pustulosis after dental infection control and dental metal removal. J Dermatol. 2017;44:695\u20138.","journal-title":"J Dermatol"},{"key":"612_CR15","first-page":"CD011628","volume":"1","author":"G Obeid","year":"2020","unstructured":"Obeid G, Do G, Kirby L, et al. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev. 2020;1:CD011628.","journal-title":"Cochrane Database Syst Rev"},{"key":"612_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/09546630802441234","volume":"20","author":"JM Ko","year":"2009","unstructured":"Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat. 2009;20:100\u20138.","journal-title":"J Dermatol Treat"},{"key":"612_CR17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fphar.2019.00282","volume":"10","author":"S Garcovich","year":"2019","unstructured":"Garcovich S, De Simone C, Genovese G, et al. Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol. 2019;10:282.","journal-title":"Front Pharmacol"},{"key":"612_CR18","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/bjd.16126","volume":"178","author":"E Stoffel","year":"2018","unstructured":"Stoffel E, Maier H, Riedl E, et al. Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics. Br J Dermatol. 2018;178:1151\u201362.","journal-title":"Br J Dermatol"},{"key":"612_CR19","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/jid.2015.186","volume":"135","author":"R Mossner","year":"2015","unstructured":"Mossner R, Frambach Y, Wilsmann-Theis D, et al. Palmoplantar pustular psoriasis is associated with missense variants in CARD14, but not with loss-of-function mutations in IL36RN in European patients. J Investig Dermatol. 2015;135:2538\u201341.","journal-title":"J Investig Dermatol"},{"key":"612_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jdermsci.2020.03.003","volume":"98","author":"M Murakami","year":"2020","unstructured":"Murakami M, Terui T. Palmoplantar pustulosis: current understanding of disease definition and pathomechanism. J Dermatol Sci. 2020;98:13\u20139.","journal-title":"J Dermatol Sci"},{"key":"612_CR21","doi-asserted-by":"publisher","unstructured":"Mahil SK, Catapano M, Di Meglio P, et al. An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target. Sci Transl Med. 2017;9:eaan2514. https:\/\/doi.org\/10.1126\/scitranslmed.aan2514.","DOI":"10.1126\/scitranslmed.aan2514"},{"key":"612_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jdermsci.2016.09.019","volume":"85","author":"R Bissonnette","year":"2017","unstructured":"Bissonnette R, Fuentes-Duculan J, Mashiko S, et al. Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway. J Dermatol Sci. 2017;85:20\u20136.","journal-title":"J Dermatol Sci"},{"key":"612_CR23","first-page":"669","volume":"16","author":"F Augey","year":"2006","unstructured":"Augey F, Renaudier P, Nicolas JF. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur J Dermatol. 2006;16:669\u201373.","journal-title":"Eur J Dermatol"},{"key":"612_CR24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2340\/00015555766871","volume":"76","author":"A Ohkawara","year":"1996","unstructured":"Ohkawara A, Yasuda H, Kobayashi H, et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background. Acta Derm Venereol. 1996;76:68\u201371.","journal-title":"Acta Derm Venereol"},{"key":"612_CR25","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/1346-8138.14523","volume":"45","author":"H Fujita","year":"2018","unstructured":"Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45:1235\u201370.","journal-title":"J Dermatol"},{"key":"612_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40257-019-00492-0","volume":"21","author":"T Takeichi","year":"2020","unstructured":"Takeichi T, Akiyama M. Generalized pustular psoriasis: clinical management and update on autoinflammatory aspects. Am J Clin Dermatol. 2020;21:227\u201336.","journal-title":"Am J Clin Dermatol"},{"issue":"Suppl 1","key":"612_CR27","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1007\/s00403-002-0371-6","volume":"295","author":"Y Umezawa","year":"2003","unstructured":"Umezawa Y, Ozawa A, Kawasima T, et al. Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res. 2003;295(Suppl 1):S43-54.","journal-title":"Arch Dermatol Res"},{"key":"612_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","volume":"28","author":"A Sidoroff","year":"2001","unstructured":"Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)\u2013a clinical reaction pattern. J Cutan Pathol. 2001;28:113\u20139.","journal-title":"J Cutan Pathol"},{"key":"612_CR29","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1365-2133.2009.09348.x","volume":"161","author":"M Brenner","year":"2009","unstructured":"Brenner M, Molin S, Ruebsam K, et al. Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment. Br J Dermatol. 2009;161:964\u20136.","journal-title":"Br J Dermatol"},{"key":"612_CR30","first-page":"83","volume":"5","author":"GA Vena","year":"2015","unstructured":"Vena GA, Cassano N, Bellia G, Colombo D. Psoriasis in pregnancy: challenges and solutions. Psoriasis (Auckl). 2015;5:83\u201395.","journal-title":"Psoriasis (Auckl)"},{"key":"612_CR31","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/bjd.18203","volume":"181","author":"E Sbidian","year":"2019","unstructured":"Sbidian E, Madrange M, Viguier M, et al. Respiratory virus infection triggers acute psoriasis flares across different clinical subtypes and genetic backgrounds. Br J Dermatol. 2019;181:1304\u20136.","journal-title":"Br J Dermatol"},{"key":"612_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2340\/00015555-2808","volume":"98","author":"K Furue","year":"2018","unstructured":"Furue K, Yamamura K, Tsuji G, et al. Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol. 2018;98:5\u201313.","journal-title":"Acta Derm Venereol"},{"key":"612_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","volume":"140","author":"A Johnston","year":"2017","unstructured":"Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140:109\u201320.","journal-title":"J Allergy Clin Immunol"},{"key":"612_CR34","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa1013068","volume":"365","author":"S Marrakchi","year":"2011","unstructured":"Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365:620\u20138.","journal-title":"N Engl J Med"},{"key":"612_CR35","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","volume":"15","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15:907\u201319.","journal-title":"Expert Rev Clin Immunol"},{"key":"612_CR36","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1038\/jid.2013.230","volume":"133","author":"K Sugiura","year":"2013","unstructured":"Sugiura K, Takemoto A, Yamaguchi M, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Investig Dermatol. 2013;133:2514\u201321.","journal-title":"J Investig Dermatol"},{"key":"612_CR37","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.jaci.2014.09.043","volume":"135","author":"S Hussain","year":"2015","unstructured":"Hussain S, Berki DM, Choon SE, et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol. 2015;135:1067\u201370 (e9).","journal-title":"J Allergy Clin Immunol"},{"key":"612_CR38","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1038\/jid.2013.214","volume":"133","author":"A Korber","year":"2013","unstructured":"Korber A, Mossner R, Renner R, et al. Mutations in IL36RN in patients with generalized pustular psoriasis. J Investig Dermatol. 2013;133:2634\u20137.","journal-title":"J Investig Dermatol"},{"key":"612_CR39","doi-asserted-by":"publisher","first-page":"e11741","DOI":"10.1097\/MD.0000000000011741","volume":"97","author":"Z Li","year":"2018","unstructured":"Li Z, Yang Q, Wang S. Genetic polymorphism of IL36RN in Han patients with generalized pustular psoriasis in Sichuan region of China: a case\u2013control study. Medicine (Baltimore). 2018;97:e11741.","journal-title":"Medicine (Baltimore)"},{"key":"612_CR40","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jdermsci.2016.10.009","volume":"85","author":"T Takeichi","year":"2017","unstructured":"Takeichi T, Togawa Y, Okuno Y, et al. A newly revealed IL36RN mutation in sibling cases complements our IL36RN mutation statistics for generalized pustular psoriasis. J Dermatol Sci. 2017;85:58\u201360.","journal-title":"J Dermatol Sci"},{"key":"612_CR41","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1038\/jid.2015.288","volume":"135","author":"DM Berki","year":"2015","unstructured":"Berki DM, Liu L, Choon SE, et al. Activating CARD14 mutations are associated with generalized pustular psoriasis but rarely account for familial recurrence in psoriasis vulgaris. J Investig Dermatol. 2015;135:2964\u201370.","journal-title":"J Investig Dermatol"},{"key":"612_CR42","doi-asserted-by":"publisher","unstructured":"Manils J, Webb LV, Howes A, et al. CARD14(E138A) signalling in keratinocytes induces TNF-dependent skin and systemic inflammation. Elife. 2020;9:e56720. https:\/\/doi.org\/10.7554\/eLife.56720.","DOI":"10.7554\/eLife.56720"},{"key":"612_CR43","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jid.2016.06.618","volume":"136","author":"SK Mahil","year":"2016","unstructured":"Mahil SK, Twelves S, Farkas K, et al. AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J Investig Dermatol. 2016;136:2251\u20139.","journal-title":"J Investig Dermatol"},{"key":"612_CR44","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ajhg.2014.04.005","volume":"94","author":"N Setta-Kaffetzi","year":"2014","unstructured":"Setta-Kaffetzi N, Simpson MA, Navarini AA, et al. AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet. 2014;94:790\u20137.","journal-title":"Am J Hum Genet"},{"key":"612_CR45","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.16232","volume":"178","author":"H Bachelez","year":"2018","unstructured":"Bachelez H. Pustular psoriasis and related pustular skin diseases. Br J Dermatol. 2018;178:614\u20138.","journal-title":"Br J Dermatol"},{"key":"612_CR46","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jaad.2011.01.032","volume":"67","author":"A Robinson","year":"2012","unstructured":"Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67:279\u201388.","journal-title":"J Am Acad Dermatol"},{"key":"612_CR47","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jaad.2008.10.055","volume":"60","author":"LC Strowd","year":"2009","unstructured":"Strowd LC, Yentzer BA, Fleischer AB Jr, Feldman SR. Increasing use of more potent treatments for psoriasis. J Am Acad Dermatol. 2009;60:478\u201381.","journal-title":"J Am Acad Dermatol"},{"key":"612_CR48","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/1346-8138.15196","volume":"47","author":"H Saeki","year":"2020","unstructured":"Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020;47:201\u201322.","journal-title":"J Dermatol"},{"key":"612_CR49","unstructured":"European Medicines Agency. Medicines. https:\/\/www.ema.europa.eu\/en\/medicines. Accessed 24 Nov 2020."},{"key":"612_CR50","unstructured":"National Institute of Clinical Excellence. Systemic biological therapy for psoriasis. https:\/\/pathways.nice.org.uk\/pathways\/psoriasis#path=view%3A\/pathways\/psoriasis\/systemic-biological-therapy-for-psoriasis.xml&content=view-index. Accessed 24 Nov 2020."},{"key":"612_CR51","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2147\/CCID.S240607","volume":"13","author":"E Freitas","year":"2020","unstructured":"Freitas E, Rodrigues MA, Torres T. Diagnosis, screening and treatment of patients with palmoplantar pustulosis (PPP): a review of current practices and recommendations. Clin Cosmet Investig Dermatol. 2020;13:561\u201378.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"612_CR52","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/1346-8138.14294","volume":"45","author":"S Sano","year":"2018","unstructured":"Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45:529\u201339.","journal-title":"J Dermatol"},{"key":"612_CR53","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/jamadermatol.2019.1394","volume":"155","author":"T Terui","year":"2019","unstructured":"Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial. JAMA Dermatol. 2019;155:1153\u201361.","journal-title":"JAMA Dermatol"},{"key":"612_CR54","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaad.2019.01.066","volume":"80","author":"U Mrowietz","year":"2019","unstructured":"Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol. 2019;80:1344\u201352.","journal-title":"J Am Acad Dermatol"},{"key":"612_CR55","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/1346-8138.14815","volume":"46","author":"A Pinter","year":"2019","unstructured":"Pinter A, Wilsmann-Theis D, Peitsch WK, Mossner R. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: report on four cases. J Dermatol. 2019;46:426\u201330.","journal-title":"J Dermatol"},{"key":"612_CR56","first-page":"940","volume":"7","author":"R Bissonnette","year":"2008","unstructured":"Bissonnette R, Poulin Y, Bolduc C, et al. Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol. 2008;7:940\u20136.","journal-title":"J Drugs Dermatol"},{"key":"612_CR57","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s13063-018-2841-y","volume":"19","author":"V Cornelius","year":"2018","unstructured":"Cornelius V, Wilson R, Cro S, et al. A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. Trials. 2018;19:465.","journal-title":"Trials"},{"key":"612_CR58","unstructured":"Clinicaltrials.gov. Initial dosing of BI 655130 in palmoplantar pustulosis patients. https:\/\/clinicaltrials.gov\/ct2\/show\/nct03135548. Accessed 15 Oct 2020."},{"key":"612_CR59","unstructured":"Clinicaltrials.gov. A study to test how effective and safe different doses of BI 655130 are in patients with a moderate to severe form of the skin disease palmoplantar pustulosis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04015518. Accessed 15 Oct 2020."},{"key":"612_CR60","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMc1811317","volume":"380","author":"H Bachelez","year":"2019","unstructured":"Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380:981\u20133.","journal-title":"N Engl J Med"},{"key":"612_CR61","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s13555-021-00504-0","volume":"11","author":"U Mrowietz","year":"2021","unstructured":"Mrowietz U, Burden AD, Pinter A, Reich K, Sch\u00e4kel K, Baum P, Datsenko Y, Deng H, Padula SJ, Thoma C, Bissonnette R. Spesolimab, an anti-interleukin-36 receptor antibody, in patients with palmoplantar pustulosis: Results of a phase IIa, multicenter, double-blind, randomized, placebo-controlled pilot study. Dermatol Ther (Heidelb). 2021;11:571\u201385.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"612_CR62","unstructured":"Clinicaltrials.gov. A study to evaluate the efficacy and safety of ANB019 in subjects with palmoplantar pustulosis (PPP). https:\/\/clinicaltrials.gov\/ct2\/show\/nct03633396. Accessed 15 Oct 2020."},{"key":"612_CR63","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/1346-8138.13306","volume":"43","author":"S Imafuku","year":"2016","unstructured":"Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43:1011\u20137.","journal-title":"J Dermatol"},{"key":"612_CR64","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/1346-8138.13622","volume":"44","author":"H Saeki","year":"2017","unstructured":"Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44:355\u201362.","journal-title":"J Dermatol"},{"key":"612_CR65","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bjd.14702","volume":"176","author":"K Yamasaki","year":"2017","unstructured":"Yamasaki K, Nakagawa H, Kubo Y, Ootaki K, Japanese Brodalumab Study Group. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176:741\u201351.","journal-title":"Br J Dermatol"},{"key":"612_CR66","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jaad.2010.02.063","volume":"63","author":"KT Amor","year":"2010","unstructured":"Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol. 2010;63:925\u201346 (quiz 47\u20138).","journal-title":"J Am Acad Dermatol"},{"key":"612_CR67","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jaad.2010.02.062","volume":"63","author":"C Ryan","year":"2010","unstructured":"Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol. 2010;63:949\u201372 (quiz 73\u20134).","journal-title":"J Am Acad Dermatol"},{"key":"612_CR68","doi-asserted-by":"crossref","unstructured":"Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis. Expert Opin Drug Saf. 2020;19(8):969\u2013980.","DOI":"10.1080\/14740338.2020.1785427"},{"key":"612_CR69","doi-asserted-by":"publisher","first-page":"66","DOI":"10.7326\/0003-4819-153-1-201007060-00030","volume":"153","author":"M Viguier","year":"2010","unstructured":"Viguier M, Guigue P, Pages C, Smahi A, Bachelez H. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist anakinra: lack of correlation with IL1RN mutations. Ann Intern Med. 2010;153:66\u20137.","journal-title":"Ann Intern Med"},{"key":"612_CR70","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/bjd.12548","volume":"170","author":"U Huffmeier","year":"2014","unstructured":"Huffmeier U, Watzold M, Mohr J, Schon MP, Mossner R. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol. 2014;170:202\u20134.","journal-title":"Br J Dermatol"},{"key":"612_CR71","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.0906-6705.2004.00205.x","volume":"13","author":"AJ Schottelius","year":"2004","unstructured":"Schottelius AJ, Moldawer LL, Dinarello CA, et al. Biology of tumor necrosis factor-alpha - implications for psoriasis. Exp Dermatol. 2004;13:193\u2013222.","journal-title":"Exp Dermatol"},{"key":"612_CR72","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000117706","volume":"216","author":"M Esposito","year":"2008","unstructured":"Esposito M, Mazzotta A, Casciello C, Chimenti S. Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series. Dermatology. 2008;216:355\u201360.","journal-title":"Dermatology"},{"key":"612_CR73","first-page":"652","volume":"8","author":"SK Saikaly","year":"2016","unstructured":"Saikaly SK, Mattes M. Biologics and pediatric generalized pustular psoriasis: an emerging therapeutic trend. Cureus. 2016;8:652.","journal-title":"Cureus"},{"key":"612_CR74","unstructured":"AnaptysBio. AnaptysBio announces orphan drug designation of imsidolimab for treatment of generalized pustular psoriasis. http:\/\/ir.anaptysbio.com\/news-releases\/news-release-details\/anaptysbio-announces-orphan-drug-designation-imsidolimab. Accessed 19 Oct 2020."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00612-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-021-00612-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00612-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T14:41:48Z","timestamp":1699627308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-021-00612-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,9]]},"references-count":74,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1007\/s13555-021-00612-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,9]]},"assertion":[{"value":"28 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}